As high-dose treatment with 5-ALA may not be applicable to patients with acute hepatic porphyria or lead poisoning 57, additional treatment with CHIL3/CHI3L1 could provide extra efficacy to mitigate HIR injury. The gene discussed is CHI3L1; the disease is hepatic porphyria.